|
|
News Breaks
|
January 23, 2012
|
| 09:09 EDT |  | PPHM |
| theflyonthewall.com: | Peregrine Pharmaceuticals shares undervalued, says Roth Capital | | After Peregrine reported positive Phase II results for its lead candidate bavituximab in NSLC, Roth Capital expects upcoming data to "generate excitement" in 2012. The firm reiterates a $10 target and Buy rating. :theflyonthewall.com |
|
|
News For PPHM From The Last 14 Days Check below for free stories on PPHM the last two weeks.
There are 2 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing. |
|
May 21, 2012
|
| 09:00 EDT | | PPHM |
| | 07:36 EDT |  | PPHM |
|
|
|
|
|
Subscribe for More Information